Subscribe
svetlana-lukienko-shutterstock-com-cash-
Svetlana Lukienko / Shutterstock.com
24 February 2016Americas

Bass returns funds but vows to continue pharma fight

Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review (IPR) challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB accepts Bass’s toenail patent challenges
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.
Americas
PTAB rejects Vimovo IPR trial
11 December 2015   The Patent Trial and Appeal Board has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.
Big Pharma
Celgene fends off Kyle Bass challenge
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
PTAB accepts Bass’s toenail patent challenges
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.
Americas
PTAB rejects Vimovo IPR trial
11 December 2015   The Patent Trial and Appeal Board has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.
Big Pharma
Celgene fends off Kyle Bass challenge
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

More on this story

Americas
PTAB accepts Bass’s toenail patent challenges
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.
Americas
PTAB rejects Vimovo IPR trial
11 December 2015   The Patent Trial and Appeal Board has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.
Big Pharma
Celgene fends off Kyle Bass challenge
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB